NAMS vs. BPMC, VKTX, IONS, CYTK, SMMT, OGN, MDGL, NUVL, BBIO, and APLS
Should you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), Organon & Co. (OGN), Madrigal Pharmaceuticals (MDGL), Nuvalent (NUVL), BridgeBio Pharma (BBIO), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
NewAmsterdam Pharma (NASDAQ:NAMS) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk.
NewAmsterdam Pharma has higher earnings, but lower revenue than Blueprint Medicines.
NewAmsterdam Pharma has a net margin of 0.00% compared to Blueprint Medicines' net margin of -102.15%. NewAmsterdam Pharma's return on equity of 0.00% beat Blueprint Medicines' return on equity.
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
NewAmsterdam Pharma has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
In the previous week, Blueprint Medicines had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 14 mentions for Blueprint Medicines and 5 mentions for NewAmsterdam Pharma. Blueprint Medicines' average media sentiment score of 0.35 beat NewAmsterdam Pharma's score of 0.32 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Blueprint Medicines received 507 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 67.89% of users gave Blueprint Medicines an outperform vote.
NewAmsterdam Pharma presently has a consensus price target of $33.25, indicating a potential upside of 72.28%. Blueprint Medicines has a consensus price target of $108.00, indicating a potential upside of 4.51%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than Blueprint Medicines.
Summary
NewAmsterdam Pharma beats Blueprint Medicines on 10 of the 17 factors compared between the two stocks.
Get NewAmsterdam Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewAmsterdam Pharma Competitors List
Related Companies and Tools
